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Abstract: Irritable bowel syndrome (IBS) is a common chronic functional disorder of the 
gastrointestinal tract, meanly characterized by recurrent abdominal pain or discomfort and altered 
bowel habit. It is a complex disorder involving biological, environmental, and psychosocial fac-
tors. The diagnosis is achieved according to the Rome III criteria provided that organic causes 
have been excluded. Although IBS does not constitute a life-threatening condition, it has a 
remarkable prevalence and profoundly reduces the quality of life with burdening socioeconomic 
costs. One of the principal concerns about IBS is the lack of effective therapeutic options. Up 
to 40% of patients are not satisfied with any available medications, especially those suffering 
from chronic constipation. A correct management of IBS with constipation should evolve 
through a global approach focused on the patient, starting with careful history taking in order 
to assess the presence of organic diseases that might trigger the disorder. Therefore, the second 
step is to examine lifestyle, dietary habits, and psychological status. On these bases, a step-up 
management of disease is recommended: from fiber and bulking agents, to osmotic laxative 
drugs, to new molecules like lubiprostone and linaclotide. Although new promising tools for 
relief of bowel-movement-related symptoms are being discovered, a dedicated doctor–patient 
relationship still seems to be the key for success.
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Introduction
Irritable bowel syndrome (IBS) is a common chronic functional disorder of the gas-
trointestinal tract, meanly characterized by recurrent abdominal pain or discomfort 
and altered bowel habit.1 The diagnosis is achieved according to the Rome III criteria 
provided that organic causes have been excluded.2 Abdominal discomfort should be 
at least 3 days per month in the last 3 months and associated with change either in 
frequency or form of stool and/or improved with defecation.3 The overall prevalence in 
European countries ranges from 6% to 12% with the peak among middle-aged women, 
but it varies according to the geographic area considered.4 The pathophysiology of IBS 
is still subject of intense research and several factors seem to be involved: visceral 
hypersensitivity, psychosocial dysfunction, gastrointestinal motility, postinfectious 
development, impaired intestinal microbiota, food sensitivity, intestinal inflammation, 
and genetic factors.5–8 Although clinical manifestations are not specific and overlap 
with many other diseases, IBS may fall into three different variants:9,10
?? IBS with constipation (IBS-C); hard/lumpy stools predominant over normal/loose 
stools.
?? IBS with diarrhea; watery/loose stools predominant over normal/lumpy stools.
?? Mixed IBS; both hard and watery stools represent ?25% of bowel movements.
A forth variant, named unsubtyped IBS due to insufficient abnormalities in stool, 
may be further identified. It must be acknowledge that these classes are inclined to 
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vary over time and patients may repeatedly switch from one 
form to another.11
Although IBS does not constitute a life-threatening condi-
tion and there is not impact on life expectancy, it profoundly 
reduces the quality of life with burdening socioeconomic 
costs.12–14 These latter costs consist of increased utilization 
of health care resources (ie, frequent visits to physicians, 
long-term medications use, redundant invasive expensive 
investigations) and reduced work productivity (ie, absentee-
ism and presenteeism).
One of the principal concerns about IBS is the lack of 
effective therapeutic options. A considerable proportion 
of patients are not satisfied with any available medications 
(up to 40%),15,16 especially those suffering from chronic 
constipation.17 Although new promising tools for relief of 
bowel-movement-related symptoms are being discovered, 
a dedicated doctor–patient relationship seems to be the key 
for success.18–22
Therefore, a narrative review of the pathophysiologic 
factors and therapeutic options of IBS associated with 
constipation is important. The aim of this work is to provide 
an overview of knowledge that is detailed and up to date 
to the clinicians to allow for better awareness and manage-
ment of IBS-C.
Pathophysiology mechanism
IBS is a complex and heterogeneous disorder whose 
pathophysiological mechanisms are poorly understood. 
Nevertheless, previous studies have proposed that motil-
ity dysfunctions, visceral hypersensitivity, and brain–gut 
interplays can represent the main pathophysiological mecha-
nisms of IBS.23,24 Evidence supports the hypothesis that IBS 
etiology is multifactorial in nature involving biological, 
environmental, and psychosocial factors. In particular, recent 
genetic studies have defined IBS as a “complex genetic 
disorder” resulting from a combination of multiple genetic 
variants (ie, several genes encoding proteins/peptides related 
to gastrointestinal function) and environmental factors (ie, 
diet, infections, stressful events).25,26 In the recent review by 
Saito, the estimated genetic liability and heritability in IBS, 
based on twin studies, ranged between 1% and 20% and 
between 0% and 57%, respectively. Moreover, the same 
author reported more than 60 genes as potentially involved 
in IBS pathogenesis and grouped them into subclasses 
according to the pathway in which they are involved (ie, 
serotonergic, adrenergic, inflammatory, or intestinal barrier 
genes).25 However, to date, there is no conclusive evidence 
regarding a concrete genetic basis able to determine IBS or 
its phenotype, and confirmation with genome-wide associa-
tion studies in IBS is still required.27,28
With regard for gastrointestinal dysmotility, the American 
Gastroenterological Association technical review underlined 
the lack of consensus on the patterns of motility responsible 
for constipation and diarrhea in IBS, although delayed 
colonic transit was seen in constipation and accelerated 
transit in diarrhea.29 It is worth noting that motility abnor-
malities may interact with low sensory thresholds to produce 
symptoms. Indeed, Serra et al30 suggested that delayed transit 
of gas causes greater abdominal perception in patients with 
IBS. More recently, Prott et al31 demonstrated new relation-
ships between certain pelvic floor dyssynergia symptoms and 
disordered anorectal physiology in patients with non-diarrhea 
predominant IBS, thus emphasizing that these patients 
with non-diarrhea predominant IBS may have pelvic floor 
dysfunction despite the fact that these two conditions are 
mutually exclusive by Rome criteria. Moreover, this study 
also showed that non-diarrhea predominant IBS patients with 
a physiological diagnosis of pelvic floor dysfunction were 
more likely to exhibit hypersensitivity to pain.31
The role of visceral hypersensitivity to a variety of stimuli 
(eg, balloon distension, electrical stimulation) has been 
extensively investigated within the setting of IBS, implicat-
ing that IBS patients display a reduced threshold to pain or 
discomfort in response to visceral stimulation, as compared 
to normal subjects.32–34 Several lines of evidence are con-
sistent with the notion that visceral hypersensitivity is not 
site-specific and can be usually documented throughout the 
whole gastrointestinal tract, suggesting a diffuse involvement 
in IBS patients.35–38 Nevertheless, the mechanisms underlying 
this enhanced visceral sensitivity, likely involving altered 
peripheral/central processing of sensory input and psychoneu-
roimmune interactions, have not been fully elucidated.39–41 
Particularly, it remains unclear what psychological factors 
are relevant for visceral hypersensitivity in IBS patients, and 
how they may interact with biological mechanisms, such as 
peripheral/central neuro–endocrine and immune processes.42 
Presence of anxiety and depression, history of sexual abuses, 
family loss, and insufficient coping strategies are just some 
of the factors that should be evaluated carefully. Currently, 
a growing interest has been focused on the complex interplay 
between the central, enteric, and autonomic nervous system, 
named the brain–gut axis. Indeed, a continuous bidirectional 
interplay between the gut and the brain occurs via neural, 
immunological, and hormonal routes, and, once altered, plays 
a pivotal role in functional gastrointestinal disorders, 
allowing transmission of emotional states from the central 
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nervous system to the gut, and perception of gastrointestinal 
changes (pain, contractions, bloating) to the central nervous 
system.43,44 Based on the assumption that IBS has a variety of 
environmental risk factors,45 they can all influence the brain–
gut axis, leading to abnormal gastrointestinal function and 
motility. Of note, recent evidence highlighted that alterations 
in gut barrier function/permeability, occurring in response, 
or in parallel, to changes in the intestinal microbiota, can 
determine aberrant host immune responses and thus may 
contribute to the IBS pathogenesis.46 This field represents 
nowadays one of the most promising and revolutionary 
aspects of medicine. However, its discussion is beyond the 
purpose of this review and would be worth considering for 
a self-standing dissertation.
Diagnosis
IBS is commonly identified by symptom-based approaches 
and, according to the Rome III criteria, the main feature of 
IBS is the presence of recurrent abdominal pain or discomfort 
that is associated with defecation and/or a change in bowel 
habit.47 With regard to IBS-C, the stool pattern is character-
ized by the presence of hard or lumpy stools (?25% of bowel 
movements) and loose or watery stools (?25% of bowel 
movements).47
It is worth noting that the clinical definition of IBS 
has been subjected to changes over the years, from the 
Manning criteria in 1978 to three consecutive iterations 
of the Rome criteria, with the most recent one (Rome III) 
in 2006. However, no significant differences in sensitivity 
among these various symptom-based criteria have been 
demonstrated.48,49 Of note, the recent cross-sectional study 
by Engsbro et al49 supported the relevance of the Rome III 
criteria for IBS in primary care, identifying a subpopulation 
of patients with qualitatively different symptoms, a higher 
symptom burden, and a lower health-related quality of life 
compared with patients not fulfilling such criteria.
Considering that IBS diagnosis consists of symptom-
based criteria, the role of a careful medical history is 
crucial, comprising all patient comorbidities and home 
therapies, which may influence the change of bowel habits.50 
Moreover, psychological status and potential trauma, such 
as family loss, sexual abuse, and unemployment, should 
be ruled out. Patients are asked for an accurate symptom 
description regarding: whether there is pain relief with 
evacuation; the eventual negative influence of stressful 
events on frequency and severity of pain presentation; the 
relation of pain to food intake; and, for women, menstrual 
cycle.51 With regard to IBS-C, patients refer to difficulty in 
passing hard/lumpy stool (ie, straining defecation, need for 
manual help), infrequent bowel movements (three or less 
bowel movements per week), and/or a sense of incomplete 
evacuation.52 In clinical practice, the Bristol scale represents 
a useful guide for the description of stool consistency and 
shape.52 In addition to identifying the presence of the above 
clinical presentation, the symptom rate is important to fulfill 
the diagnostic criteria, which require their occurrence on at 
least 3 days per month in the last 3 months to indicate current 
activity, and at least 6 months before the patient presents to 
substantiate that IBS is a chronic disorder.47 Furthermore, the 
absence of alarm signs and symptoms (including new onset 
of symptoms in those ?50 years of age, unintentional weight 
loss, signs of gastrointestinal bleeding, nocturnal symptoms, 
family history of gastrointestinal diseases) is mandatory to 
confidently suppose the diagnosis of a functional disease 
such as IBS.53–55
According to the American College of Gastroenterol-
ogy Task Force on IBS, clinical investigations to exclude 
organic cause are not recommended in patients who meet 
the IBS Rome III criteria and lack any alarm features.3 
In the setting of IBS-C, patients with severe and/or refrac-
tory constipation may undergo a more accurate diagnostic 
workup including colonic transit time, anorectal manometry, 
and defecography.56
Current evidences point out a significant degree of overlap 
between IBS and other functional gastrointestinal disorders,57 
with various upper and lower gastrointestinal tract symptoms 
that may occur in the same patients and fluctuate over time.58 
Thus, the possibility to distinguish these entities is somewhat 
of a challenge for gastroenterologists. In this context, Wong 
et al59 showed that patients identified by the Rome III crite-
ria for functional constipation and IBS-C share bowel and 
abdominal symptoms, as well as most of the available drug 
therapies. Thus making it difficult to clearly discriminate 
the two disorders. Shekhar et al60 highlighted that patients 
with IBS-C or functional constipation had similar baseline 
symptoms, bowel habits, orocecal and colonic transit, and 
fasting concentrations of serotonin. However, only patients 
with IBS-C had an increase in abdominal symptoms after 
meal ingestion. Of note, this study showed that increased 
platelet-depleted plasma 5-HT concentration was associated 
with reduced visceral sensitivity and stool frequency both 
in patients with functional constipation and IBS-C.60 More 
recently, the results of a community survey by Rey et al61 
concluded that functional constipation is supposed to be a 
spectrum, in which most patients do not have abdominal 
pain but other patients have IBS or are out of any currently 
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established diagnosis. A previous study from our group 
showed a higher concentration and excretion rate of methane 
(CH4) in breath samples among functional constipation com-
pared to IBS-C, thus supposing that different mechanisms are 
involved in their genesis.62 However, it must be pointed out 
that the wide overlap existing between the two groups does 
not allow us to use the Breath Test as a reliable diagnostic 
tool to discriminate them. Similarly, it cannot discriminate 
them from prolonged OCTT due to organic diseases (ie, sys-
temic sclerosis).63 Overall, on the basis of current and future 
epidemiological and pathophysiological studies, the Rome 
III criteria will likely continue to evolve to provide the most 
appropriate characterization of patients with functional bowel 
symptoms.64 A flow chart summarizing the mean diagnostic 
process for IBS-C patients is depicted in Figure 1.
Role of radiologic investigations
The matter of radiologic imaging impact in diagnosis and 
management of patients with IBS has already been widely 
discussed in literature, especially considering those cases 
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Figure 1 Diagnostic ﬂowchart of patients referring to specialists for chronic constipation and abdominal discomfort.
Abbreviations: CC, chronic constipation; CT, computed tomography; FOBT?, fecal occult blood test positive; IBS-C, irritable bowel syndrome constipation variant; LhBT, 
Lactulose breath test; OCTT, orocecal transit time.
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in which symptoms can be the expression of an underlying 
disease with specific structural modifications;65 however, it is 
particularly important to highlight that the presence of such 
alterations does not necessarily exclude the diagnosis of IBS, 
and it could help physicians to address their attention to the 
choice of the most suitable imaging modality, considering 
the most likely differential diagnoses and the most typical 
symptoms. Guidelines based on systematic reviews may 
prescribe the use of bowel imaging, abdominal ultrasound 
(US), and computed tomography (CT) in IBS, suggesting 
that these modalities should address the most likely under-
lying disease.66 The clearest example of the role played by 
diagnostic imaging is represented by pelvic or abdominal US 
performed in patients reporting abdominal pain with biliary 
features and rise of liver enzymes, since the overlap between 
IBS and gall stones is a well-known entity.67 However, phy-
sicians should be prudent in the evaluation of gallbladder 
US findings in IBS, and radiological assessment should be 
limited to patients with typical meal-provoked symptoms. 
Little attention in literature has been paid regarding the 
application of barium enema or CT colonography in IBS; 
the American College of Gastroenterology guidelines sug-
gest that patients with IBS requiring further investigations 
should undergo colonoscopy rather than barium enema or 
CT colonography, because of their inability to perform ran-
dom biopsies. However, in patients with IBS-C, no colonic 
examinations are suggested over others (conventional 
colonoscopy, CT colonography, barium enema) to investi-
gate causes of mechanical obstruction.68 Other radiological 
approaches to IBS are represented by calculation of colonic 
transit time by use of radiopaque markers, defecography 
(or more recently magnetic resonance defecography),69 and 
quantitative analysis of bowel gas using plain abdominal 
radiograph.70 In particular, the evaluation of bowel transit 
alterations in IBS has been proposed, although its value is 
not completely clear; the use of radiopaque markers may 
provide important information about dysmotility and about 
accelerated or delayed transit time but no correlations of 
clinical significance have ever been found between transit 
data and specific gastrointestinal symptoms.71,72 The study 
of colonic transit based on ingested radiopaque markers has 
been widely used and it can be useful in studying slow tran-
sit constipation, providing an evaluation of the progression 
time (monitored 24 hours and 5 days after administration of 
about 30 inert cylinders on plain abdominal X-rays) of the 
markers through the large intestine. A modification in the 
distribution of markers in the bowel may suggest a colonic 
dysmotility. As a consequence, the results of marker studies 
have a clinical impact in the management of patients with 
constipation-variant IBS.73 Very recently, the use of LhBT 
combined with abdominal MRI has shown promising results 
in extimating OCTT.74 Defecography is another interesting 
radiologic modality that can provide important information: it 
is a morphodynamic examination that evaluates the presence 
of rectum and pelvic floor disorders by documenting the act 
of defecation using semisolid barium through videofluoro-
graphic recording.75 In recent years, a novel modality called 
magnetic resonance defecography, consisting of defecogra-
phy by magnetic resonance imaging, has been developed: 
it can allow a panoramic visualization of rectum and pelvic 
floor compartments, with dynamic images providing morpho-
logical and functional information with sparing of ionizing 
radiations.75 However, it is important to underline that in the 
last years these modalities have shown a limited impact on 
IBS, which still remains basically a clinical entity.
Treatment
In the last decade, the management of IBS was symptom-
based. Actually, the recent advance in the understanding of 
the complex interaction between gut, immune system, and 
nervous system (the so called gut–brain axis) has led to an 
increase in the therapeutic arsenal for relief of both bowel-
movement-related symptoms and pain.76 Moreover, the 
evaluation of drug efficacy in IBS underwent major changes 
especially with regard to trial design and clinical endpoints,77 
from a single endpoint to a so-called binary endpoint.
The USA Food and Drug Administration (FDA) recom-
mended the focus on two of the most relevant aspects of IBS: 
abdominal pain and defecation disorder.78 In particular, in 
predominant IBS-C, responder definition includes a more 
than 30% reduction from baseline in the weekly mean of 
the daily scores for worst abdominal pain and an increase 
of more than one complete spontaneous bowel movement 
(CSBM) per week from baseline, both in the same week, for 
at least 50% of the treatment period weeks.
Also, the Europeans Medicines Agency (EMA) in January 
2014 finalized a new guideline about medical products pro-
posed for IBS treatment. Based on Rome III criteria, two co-
primary endpoints – that is, abdominal pain and evaluation of 
stool frequency for IBS-C (based on the number of CSBMs per 
week) – were considered. This change allows easier compari-
son with the FDA endpoints.79 Using those restrictive binary 
endpoints, the prokinetic molecule prucalopride (ie, selective 
5-HT4 receptor agonist), despite promising therapeutic effects 
without significant cardiovascular events to date, is not cur-
rently approved in the USA or Europe in IBS-C patients.80,81
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Nowadays, lubiprostone and linaclotide are the 
prosecretory agents available in IBS-C with a significant 
difference from the placebo according to the new standard 
proposed by the FDA and EMA. Specifically, lubiprostone 
received approval only for a subgroup of patients with IBS 
(women ?18 years old),82 whereas linaclotide is contrain-
dicated by the FDA in pediatric patients up to 6 years of age 
and its administration should be avoided in pediatric patients 
6–17 years of age.83,84 Several other agent with serotonergic 
action have been proposed for IBS with diarrhea. However, 
most of them have been withdrawn due to severe adverse 
events or their indication restricted to chronic constipation. 
Tegaserod is still available, with some exceptions, in women 
with severe IBS-C. A summary of serotonergic and prosecre-
tory agents is presented in Table 1.
However, to think that these innovative drugs are the 
final solution for patients suffering from IBS-C would be a 
mistake. Their efficacy is still under assessment and a dedi-
cated doctor–patient relationship still seems to be the key for 
a successful treatment. Strength of the recommendations and 
quality of the evidences supporting the therapeutic options 
are summarized in Table 2.
A correct management of IBS-C should be a global 
approach focused on the patient, starting with careful history 
taking in order to assess the presence of organic diseases 
that might trigger the disorder. Therefore, the second step 
is to examine lifestyle, dietary habits, and psychological 
status. On these bases, a step-up management of disease is 
recommended: from fiber and bulking agents, to osmotic 
laxative drugs, to new molecules like lubiprostone and lina-
clotide (Figure 2).
Lifestyle and dietary changes
During a first assessment, it is necessary to evaluate care-
fully dietary and lifestyle history, seeking for nutrition status, 
lack of physical activity, dietary fiber intake, and of suitable 
times for defecation. These are common problems which are 
involved in the development of IBS-C.85
As a consequence of first assessment, the initial treatment 
begins most of the time with lifestyle modifications, which 
include changes in fluids intake, exercise, and diet. Adequate 
hydration and fiber intake are considered by the majority of 
physicians to be key to beneficial clinical care and preventing 
problems, such as constipation, particularly in children and 
elderly. Regrettably, data to support these interventions are 
limited. In particular, even though the increase of dietary fiber 
and fluids intake is a standard recommendation for patients with 
IBS-C, its efficacy is controversial.86,87 Some studies suggested 
that principal sources of dietary fiber, such as bran, cereals, veg-
etables, and fruits, might actually exacerbated symptoms in IBS 
(ie, fructans, galacto-oligosaccharide, and sugar polyols).88
In this regard, in recent years, many studies have been con-
ducted on the role of fermentable, oligo-, di-, monosaccharides, 
and polyols (FODMAPs)-eliminating diets. These are 
Table 1 Serotonergic and prosecretory agents
5-HT3 antagonists Agent Adverse events Indication
? Bowel sensitivity
? Intestinal motility
Alosetron Recommendation: weak
Evidence: moderate
Severe constipation
Ischemic colitis
Only for woman suffering with  
severe IBS-D that is disabling
Cilansetron Not available Constipation Poorly introduced into clinical  
practiceRamosetron*
5-HT4 agonists
? Secretion
? Peristaltic reﬂex
? Intestinal motility
Tegaserod Better than placebo  
in promoting intestinal  
motility
Cardiovascular effects
Nausea, diarrhea, headache
Women with IBS-C (withdrawn 
in USA)
Prucalopride Not approved in IBS-D Nausea, diarrhea, headache Chronic Constipation (Canada  
and European Union)
Mixed 5-HT3/5-HT4
Renzapride Equal to placebo Nausea, diarrhea, headache, 
arrhythmias
Not available in most  
developed countries
Cisapride Withdrawn
Prosecretory agents
? Secretion
? Bowel sensitivity
Lubiprostone  
(CIC-2 agonist)
Recommendation: strong
Evidence: high
Diarrhea IBS-C
Linaclotide  
(GCC agonist)
Recommendation: strong
Evidence: moderate
Diarrhea, ﬂatulence IBS-C
Note: *Available in Japan, Korea, and Thailand.
Abbreviations: ?, increase; ?, decrease; CIC-2, chloride channel type 2; GCC, guanylate cyclase-C; HT, hydroxytryptamine receptor; IBS-C, constipation-predominant 
irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel syndrome.
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carbohydrates found in foods such as apples, pears, honey, 
sweeteners, onions, and milk (Table 3), but not all “sugars” 
are part of this group.89 They are characterized by being 
osmotic, mainly not digested or absorbed, and thus fermented 
by the intestinal bacteria.
Review papers have encouraged application of a FOD-
MAP eliminating diet as a first-line dietary approach to 
manage functional symptoms seen in IBS.90 However, further 
evaluation is necessary since the low FODMAPs diet has been 
also shown to change the intestinal microbiota, and further 
assessments of its nutritional implications are required.91
Fiber
Most physicians recommend the use of dietary fiber and 
bulking agents to regularize bowel function and to reduce 
meteorism and pain in patients with IBS. The level of evi-
dences supporting this recommendation, however, is poor.
The recommended adult daily intake of fiber ranges 
between 20 and 35 g/d. Often, many IBS-C patients modify 
their dietary fiber intake prior to the assessment of the 
physician with the belief that fiber supplementation has a 
beneficial effect on their symptoms.92 Nevertheless, fiber 
supplementation is also the treatment most often prescribed 
in the primary care system.93
The term “dietary fiber” includes carbohydrates which are 
not hydrolyzed or absorbed in the upper digestive tract and 
therefore reach the colon where they are fermented by the 
gut microbiota, producing short-chain fatty acids and gases. 
Depending on their solubility in water, fibers are subdivide 
into soluble and insoluble. An increase of the daily intake of 
fiber is able to determine softer and bulkier stools, promoting 
peristalsis and facilitating defecation.
In a randomized placebo-controlled trial,94 Bijkerk et al 
compared the efficacy of soluble (psyllium) and insoluble 
(bran) fiber versus placebo in IBS patients. They reported 
an improvement in the severity of symptoms in the psyl-
lium arm compared to placebo except for abdominal pain or 
health-related quality of life. Bran did not lead to significant 
changes in terms of symptoms and is found to be poorly 
tolerated by patients.
Partially hydrolyzed guar gum is a soluble, non-gelling 
fiber that has been shown to reduce symptoms and decrease 
abdominal pain in patients with IBS-C.95 Moreover, partially 
hydrolyzed guar gum seems to also have prebiotic proper-
ties (eg, it increases the colonic contents of short-chain fatty 
acids, lactobacilli, and Bifidobacterium).96,97 For this reason, it 
has been used in combination with rifaximin for the manage-
ment of small intestinal bacterial overgrowth.98
In a recent meta-analysis, Moayyedi et al showed that 
soluble, but not insoluble, fiber was effective in reducing 
overall symptoms.99 Their study showed that there is a 
moderate quality of evidence that fibers are effective in IBS 
patients. Taking into consideration their low costs and mini-
mal side effects, fibers still represent so far a first fundamental 
approach in the therapy of patients with IBS.
Osmotic laxatives
Similar to fibers, laxatives remain an appropriate therapy for 
many patients with IBS-C because of their relative safety, 
low cost, and availability.100
Table 2 Strength of the recommendations and quality of evidences of therapeutic options for IBS associated with constipation
Strategies Mechanism Recommendation Quality of evidence
Fibers Beneﬁt on constipation but  
may worsen bloating and  
abdominal discomfort
Weak Moderate
Fluid Evidence of a real beneﬁt is lacking Weak Very low
Probiotics Inﬂuence on stool composition  
and food fermentation through  
positive effect on intestinal  
microbiota composition
Weak Low
Laxatives The effect is mainly on constipation  
with minor or no beneﬁt on IBS  
symptoms
Weak Low
Diet Minority of patients have beneﬁt  
on bloating and meteorism
Weak Low
Linaclotide Prokinetic and secretive effect; might  
reduce visceral hypersensitivity
Strong High
Lubiprostone Prokinetic and secretive effect; might  
reduce visceral hypersensitivity
Strong Moderate
Abbreviation: IBS, irritable bowel syndrome.
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Laxatives can be classified according to the principal 
mechanism of action as:
?? osmotic laxatives; they are represented by ions or molecules 
that are osmotically active and poorly absorbed in the gut, and 
that induce secretion of water inside the intestinal lumen.
?? secretagogues and agents acting directly on epithelial 
cells, nerve cells, and smooth muscle of the gut; several 
compounds play a laxative effect through different 
mechanisms of motor activity and bowel control, and 
also act on the mucosal transport and motility.
?? lubricating agents; mineral oils (such as Vaseline oil) can 
be administered both orally and rectally; they help fecal 
expulsion and create a soft fecal mass.
?? Stimulant laxatives, for example, sodium picosulfate and 
bisacodyl, are usually used in clinical practice, but their 
effectiveness in IBS-C has not been well demonstrated yet.
Figure 2 Therapeutic ﬂowchart of patients referring for IBS-C
Notes: Use of prucalopride in IBS is considered off-label. Although illustrated at the end of therapeutic process, psychological approaches might be considered alongside 
the other treatment options.
Abbreviations: ?, increase; FODMAPs, fermentable, oligo-, di-, monosaccharides, and polyols; IBS, irritable bowel syndrome; IBS-C, IBS constipation variant; OCTT, orocecal 
transit time.
,%6&
/LIHVW\OHPRGLILFDWLRQV
±Ĺ)LEHUVDQGIOXLGV
±Ĺ3K\VLFDOH[HUFLVH
±$GYLVHRQWRLOHWLQJURXWLQH
5HVSRQVH
1RUHVSRQVH
2VPRWLFVWLPXODQWOD[DWLYH
%XONIRUPLQJOD[DWLYHV
0DLQWDLQ
&RQVLGHU
)2'0$3V
5HVSRQVH
1RUHVSRQVH
5HVSRQVH
1RUHVSRQVH
3URORQJHG2&77"
<HV 1R
&RQVLGHU
7HJDVHURG
3UXFDORSULGH
&RQVLGHU
/LQDFORWLGH
/XELSURVWRQ
&RQVLGHUFRDGMXYDQWHIIHFWRIFRJQLWLYHEHKDYLRUDO
WKHUDS\G\QDPLFSV\FKRWKHUDS\DQGK\SQRWKHUDS\
Therapeutics and Clinical Risk Management 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
699
Management of IBS-C
Osmotic laxatives, such as polyethylene glycol (PEG), 
milk of magnesia, and sorbitol are often recommended for 
IBS-C. However, data proving their efficacy on constipation 
come principally from studies on chronic constipation. The 
2005 American College of Gastroenterology summary state-
ment gave PEG a grade A recommendation for the treatment 
of patients with chronic constipation.101 Moreover, Dipalma 
et al published a randomized, multicenter, placebo-controlled 
trial of PEG laxative for chronic treatment of chronic con-
stipation.102 In this trial, 304 subjects (75 of which were 
65 years old) who met the definition of constipation based 
on modified rome criteria were enrolled. One hundred and 
seventy subjects followed therapy for 6 months. The study 
proved PEG’s safety and efficacy.
Finally, a recent placebo-controlled trial in IBS-C high-
lighted the power of PEG in increasing bowel frequency but 
also its limited effect on abdominal pain.103
Serotonergic agents
These agents fall into three categories according to their 
mechanism of action: 5-HT3 antagonists, 5-HT4 agonists, 
and mixed 5-HT3 antagonists/5-HT4 agonists.
5-HT3 antagonists have shown a potential role in reducing 
visceral sensitivity (ie, pain threshold) but to the detriment 
of intestinal motility. For this reason, they are not suitable 
for IBS-C variant.
5-HT4 agonists increase intestinal secretion, peristaltic 
reflex, and gastrointestinal transit. Among these, tegaserod 
showed good efficacy compared to placebo. The initial 
dose suggested is 6 mg orally twice a day before meals for 
4–6 weeks. In case of benefit, it should be maintained for 
other 4–6 weeks. However, due to cardiac adverse events, it 
has been removed from the USA market and its indication 
limited to females with the IBS-C variant. As mentioned 
before, prucalopride also provided good efficacy in consti-
pation but not in discomfort relief. Thus, it is available in 
Canada and the European Union for patients with chronic 
constipation (initial dose: 2 mg/day orally for 4 weeks with-
out food; maintenance: 12 weeks; then reevaluation). Solid 
data in IBS patients are still awaited.
Mixed 5-HT3 antagonists/5-HT4 agonists were supposed 
to mitigate the side effects of serotonergic agents while 
preserving their action on visceral sensitivity and secretion. 
However, several studies did not show a significant benefit 
compared to placebo.9 Cisapride, one of the most studied and 
employed drugs in clinical practice, is no longer available in 
most developed countries.
Prosecretory agents
Lubiprostone
The primary mechanism of action of lubiprostone is the 
capability to activate specific type-2 chloride channels 
(ClC-2) on the apical membrane of the enterocyte.104 They 
are involved in ion and fluid transport across epithelial 
membrane. Once channels are opened, chloride enters the 
enterocyte in the basal membrane through the action of 
Na–K–2Cl active cotransporters, creating the electrochemi-
cal gradient favoring chloride secretion leading to an overall 
concentration-dependent increase in intestinal fluid secre-
tion without altering serum sodium and potassium levels.105 
These mechanisms explain how lubiprostone increases the 
number of CSBMs per week, but its action on other IBS-C 
symptoms, such as the abdominal pain score, is only par-
tially characterized and needs further investigations. The 
suggested dosage is 8 ?g orally twice a day with food and 
water. The most common treatment-related adverse events 
(?1% of patients) involved the gastrointestinal system: diar-
rhea (6.5%), nausea (6.3%), abdominal distention (3.7%), 
abdominal pain (2.9%), flatulence (2.1%), upper abdominal 
pain (1.9%), and vomiting (1.2%). The genesis of lubipro-
stone’s adverse events remains speculative. Moreover, the 
very different baseline characteristics between patients with 
IBS-C in terms of abdominal symptoms, visceral sensitivity, 
and somatization might alter patients’ reporting of adverse 
events.106
Linaclotide
Linaclotide, a 14-amino acid synthetic peptide, is a first-in-
class, high-affinity guanylate cyclase C (GC-C) agonist. It is 
homologous to the paracrine peptide hormones guanylin and 
uroguanylin, which are the endogenous activators of GC-C.107 
This drug may modulate the intestinal physiology in two 
Table 3 Principal foods containing fermentable, oligo-, di-, 
monosaccharides, and polyols
“Sugars” Foods
Oligosaccharides:
– Fructans
– Galactans
–  Wheat, rye, onions, garlic,  
asparagus, broccoli, cabbage,  
pasta, chicory, etc.
– Legumes
Disaccharide lactose Milk, cheeses, and yogurt
Monosaccharide fructose Honey, apple, pear, mango,  
high fructose corn syrup, fruit  
juice, etc.
Polyols Apples, pears, apricot, stone  
fruit, sweeteners, confectionary, 
mushrooms, etc.
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ways. Firstly, GC-C activation leads to increased intracellular 
concentrations of the second messenger cyclic guanosine 
monophosphate (cGMP).107 Elevated intracellular cGMP 
levels activate the cGMP-dependent protein kinase II, leading 
to the phosphorylation and activation of the cystic fibrosis 
transmembrane conductance regulator (CFTR).108,109 CFTR 
activation results in the secretion of chloride and bicarbonate 
ions and inhibition of sodium absorption, leading to increased 
water flow into the intestine and the acceleration of gastroin-
testinal transit.107–110 Secondly, linaclotide has also been shown 
to reduce visceral hypersensitivity in stress- and inflammation-
induced animal models of visceral pain.111 A recent preclinical 
study suggests that, upon GC-C activation, cGMP is actively 
transported across the basolateral membrane of the intestinal 
epithelium into the submucosal space where it acts to reduce 
the mechanosensitivity of colonic nociceptors, in both healthy 
mice and a mouse model of visceral hypersensitivity.112 The 
recommended dosage is 290 ?g orally once a day before 
meals. The most frequent adverse events with linaclotide 
were diarrhea, abdominal pain, flatulence, headache, viral 
gastroenteritis, and abdominal distension.113 Diarrhea, which 
is the most common, is estimated to occur in less the 20% 
of patients and it is probably due to increased fluid secretion 
and accelerated colonic transit.114–116
Psychological therapies
The recent monograph on IBS and chronic idiopathic 
constipation by the American College of Gastroenterology 
has recognized a potential role of psychological therapies 
in IBS. Specifically, hypnotherapy, cognitive behavioral 
therapy, and dynamic psychotherapy provided signifi-
cant benefits compared to placebo.117 Other approaches 
showed no significant effects; however, the complexity 
of conducting blind and controlled studies that allow 
an objective comparison of these interventions must be 
acknowledged.
Conclusion
IBS is a multifactorial functional disorder that involves 
mainly the lower gastrointestinal tract. The major problem 
met by doctors is the relative paucity of therapeutic options 
available and their often limited efficacy. This is particularly 
emphasized in the IBS-C variant. Incomplete understand-
ing of the pathophysiology, overlap with other functional 
disorders, inter-/intraindividual variability, and patient’s 
distress contribute to the failure. We believe that a standard-
ized and step-wise approach to these patients might partially 
improve the success rate of the treatment and guarantee 
uniformity and therapeutical continuity in a setting where 
multiple investigators are often involved. In the context of 
functional disorders, a dedicated doctor–patient relationship 
still remains of utmost importance.
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